FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000596580> ?p ?o ?g. }

• W2000596580 endingPage "111" @default.
• W2000596580 startingPage "105" @default.
• W2000596580 abstract "The split-course concurrent thoracic radiation therapy (TRT) and full-dose chemotherapy for unresectable stage III non-small cell lung cancer (NSCLC) has produced promising results by comparison with the sequential approach. Instead of split-course radiation, we conducted a phase II study to investigate the feasibility of continuous concurrent TRT and chemotherapy. Twenty-two patients with unresectable NSCLC were enrolled onto a phase II study of continuous concurrent radiotherapy and chemotherapy. Treatment consisted of two courses of cisplatin (80 mg/m(2) on days 1 and 29), vindesine (3 mg/m(2) on days 1, 8, 29 and 36), and mitomycin (8 mg/m(2) on days 1 and 29). TRT began on day 2 at a dose of 60 Gy (2 Gy per fraction and 5 fractions per week for a total of 30 fractions). Of 22 patients assessable for response, none achieved a CR and 17 (77.3%) achieved a PR with an overall response rate of 77.3% (95% confidence interval, 54.6-92.2%). Grade 3 or 4 leukopenia was observed in 5/13 (81.8%) patients. Six patients (27.3%) experienced > or = grade 3 thrombocytopenia. Non-hematological toxicity was relatively mild. The overall median survival time was 19.0 months and the 1- and 2-year survival rates were 84.8 and 34.5%, respectively. It was possible to administer two courses of chemotherapy in 18 patients (81.8%) as planned. Nineteen (86.4%) of the 22 patients received the planned 60 Gy radiation. It seems to be difficult to administer the planned treatment without any interruption for the majority of patients. However, in the selected patients who completed the 60 Gy TRT, nearly half of the patients completed TRT without interruption. This combination regimen is considered to be feasible on condition that the stopping rule of the treatment is followed. We recommend administering radiotherapy continuously as far as possible." @default.
• W2000596580 created "2016-06-24" @default.
• W2000596580 creator A5001631780 @default.
• W2000596580 creator A5003703815 @default.
• W2000596580 creator A5008494874 @default.
• W2000596580 creator A5009766343 @default.
• W2000596580 creator A5031144742 @default.
• W2000596580 creator A5037986570 @default.
• W2000596580 creator A5044361715 @default.
• W2000596580 creator A5055538053 @default.
• W2000596580 creator A5066357817 @default.
• W2000596580 creator A5081566380 @default.
• W2000596580 date "2002-04-01" @default.
• W2000596580 modified "2023-10-16" @default.
• W2000596580 title "A phase II study of continuous concurrent thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III non-small cell lung cancer" @default.
• W2000596580 cites W1751540033 @default.
• W2000596580 cites W1839238860 @default.
• W2000596580 cites W1930978022 @default.
• W2000596580 cites W1944220675 @default.
• W2000596580 cites W1955985599 @default.
• W2000596580 cites W1975081329 @default.
• W2000596580 cites W1975549289 @default.
• W2000596580 cites W1996308010 @default.
• W2000596580 cites W2005341722 @default.
• W2000596580 cites W2029409133 @default.
• W2000596580 cites W2040399379 @default.
• W2000596580 cites W2045313863 @default.
• W2000596580 cites W2051767374 @default.
• W2000596580 cites W2064680538 @default.
• W2000596580 cites W2091693402 @default.
• W2000596580 cites W2108818400 @default.
• W2000596580 cites W2130652363 @default.
• W2000596580 cites W2138310931 @default.
• W2000596580 cites W2142764975 @default.
• W2000596580 cites W2261537552 @default.
• W2000596580 cites W2312703485 @default.
• W2000596580 cites W2317448174 @default.
• W2000596580 cites W3041047318 @default.
• W2000596580 cites W4317564151 @default.
• W2000596580 doi "https://doi.org/10.1016/s0169-5002(01)00460-3" @default.
• W2000596580 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11891041" @default.
• W2000596580 hasPublicationYear "2002" @default.
• W2000596580 type Work @default.
• W2000596580 sameAs 2000596580 @default.
• W2000596580 citedByCount "6" @default.
• W2000596580 countsByYear W20005965802021 @default.
• W2000596580 crossrefType "journal-article" @default.
• W2000596580 hasAuthorship W2000596580A5001631780 @default.
• W2000596580 hasAuthorship W2000596580A5003703815 @default.
• W2000596580 hasAuthorship W2000596580A5008494874 @default.
• W2000596580 hasAuthorship W2000596580A5009766343 @default.
• W2000596580 hasAuthorship W2000596580A5031144742 @default.
• W2000596580 hasAuthorship W2000596580A5037986570 @default.
• W2000596580 hasAuthorship W2000596580A5044361715 @default.
• W2000596580 hasAuthorship W2000596580A5055538053 @default.
• W2000596580 hasAuthorship W2000596580A5066357817 @default.
• W2000596580 hasAuthorship W2000596580A5081566380 @default.
• W2000596580 hasConcept C126322002 @default.
• W2000596580 hasConcept C141071460 @default.
• W2000596580 hasConcept C143998085 @default.
• W2000596580 hasConcept C2776256026 @default.
• W2000596580 hasConcept C2776694085 @default.
• W2000596580 hasConcept C2776755627 @default.
• W2000596580 hasConcept C2778239845 @default.
• W2000596580 hasConcept C2779321808 @default.
• W2000596580 hasConcept C2779338040 @default.
• W2000596580 hasConcept C2779429289 @default.
• W2000596580 hasConcept C2780873365 @default.
• W2000596580 hasConcept C31760486 @default.
• W2000596580 hasConcept C509974204 @default.
• W2000596580 hasConcept C71924100 @default.
• W2000596580 hasConcept C90924648 @default.
• W2000596580 hasConceptScore W2000596580C126322002 @default.
• W2000596580 hasConceptScore W2000596580C141071460 @default.
• W2000596580 hasConceptScore W2000596580C143998085 @default.
• W2000596580 hasConceptScore W2000596580C2776256026 @default.
• W2000596580 hasConceptScore W2000596580C2776694085 @default.
• W2000596580 hasConceptScore W2000596580C2776755627 @default.
• W2000596580 hasConceptScore W2000596580C2778239845 @default.
• W2000596580 hasConceptScore W2000596580C2779321808 @default.
• W2000596580 hasConceptScore W2000596580C2779338040 @default.
• W2000596580 hasConceptScore W2000596580C2779429289 @default.
• W2000596580 hasConceptScore W2000596580C2780873365 @default.
• W2000596580 hasConceptScore W2000596580C31760486 @default.
• W2000596580 hasConceptScore W2000596580C509974204 @default.
• W2000596580 hasConceptScore W2000596580C71924100 @default.
• W2000596580 hasConceptScore W2000596580C90924648 @default.
• W2000596580 hasIssue "1" @default.
• W2000596580 hasLocation W20005965801 @default.
• W2000596580 hasLocation W20005965802 @default.
• W2000596580 hasOpenAccess W2000596580 @default.
• W2000596580 hasPrimaryLocation W20005965801 @default.
• W2000596580 hasRelatedWork W2036782671 @default.
• W2000596580 hasRelatedWork W2048171436 @default.
• W2000596580 hasRelatedWork W2054932891 @default.
• W2000596580 hasRelatedWork W2082618265 @default.
• W2000596580 hasRelatedWork W2366392510 @default.
• W2000596580 hasRelatedWork W2381460883 @default.

• next